相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Protamine-Based Strategies for RNA Transfection
Natalia Teresa Jarzebska et al.
PHARMACEUTICS (2021)
Antibody-Drug Conjugates: A Comprehensive Review
Puregmaa Khongorzul et al.
MOLECULAR CANCER RESEARCH (2020)
Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia
Christopher A. Eide et al.
LEUKEMIA (2020)
The regulation and function of CD20: an enigma of B-cell biology and targeted therapy
Gabriela Pavlasova et al.
HAEMATOLOGICA (2020)
Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects
H. Yesid Estupinan et al.
BLOOD ADVANCES (2020)
Progress in Cancer Research, Prevention, and Care
Richard L. Schilsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Antibody-Drug Conjugates: The Last Decade
Nicolas Joubert et al.
PHARMACEUTICALS (2020)
Role of CD20+ T cells in multiple sclerosis: implications for treatment with ocrelizumab
Stefan Gingele et al.
NEURAL REGENERATION RESEARCH (2020)
Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model
Irfana Muqbil et al.
HELIYON (2019)
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
David Hong et al.
ONCOLOGY (2019)
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Kyoji Tsuchikama et al.
PROTEIN & CELL (2018)
Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth
Nicole Baeumer et al.
PLOS ONE (2018)
Folate-targeted selenium nanoparticles deliver therapeutic siRNA to improve hepatocellular carcinoma therapy
Yu Xia et al.
RSC ADVANCES (2018)
The Amount of Apoptosis Predicts Outcome in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL)
Giovanni Del Poeta et al.
BLOOD (2018)
Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia
Nisar A. Amin et al.
CLINICAL CANCER RESEARCH (2017)
Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Georg Lenz
JOURNAL OF CLINICAL ONCOLOGY (2017)
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Hsu-Ping Kuo et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Immunoprotein-Mediated siRNA Delivery
Nicole Balmer et al.
MOLECULAR PHARMACEUTICS (2017)
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib
Varinder Kaur et al.
ANNALS OF HEMATOLOGY (2017)
Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown
Nicole Baeumer et al.
NATURE PROTOCOLS (2016)
Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth
Jun Chen et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Intracellular trafficking and exocytosis of a multi-component siRNA nanocomplex
Ravi S. Shukla et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2016)
Optimized Near-IR Fluorescent Agents for in Vivo Imaging of Btk Expression
Eunha Kim et al.
BIOCONJUGATE CHEMISTRY (2015)
Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma
Idit Sagiv-Barfi et al.
BLOOD (2015)
Antibody-Mediated Delivery of Anti-KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer
Sebastian Baeumer et al.
CLINICAL CANCER RESEARCH (2015)
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
R. Angelo de Claro et al.
CLINICAL CANCER RESEARCH (2015)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study
Nora Liu et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2015)
Stability, Intracellular Delivery, and Release of siRNA from Chitosan Nanoparticles Using Different Cross-Linkers
Maria Abdul Ghafoor Raja et al.
PLOS ONE (2015)
Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An Open-Label, Phase I, Single-Dose Study in Healthy Men
Ellen Scheers et al.
DRUG METABOLISM AND DISPOSITION (2015)
Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia
Stuart A. Rushworth et al.
BLOOD (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor
Anna Turetsky et al.
SCIENTIFIC REPORTS (2014)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia
Dieter Hoelzer
CURRENT OPINION IN ONCOLOGY (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma
Jie Gao et al.
BIOMATERIALS (2012)
Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas
Tara L. Naylor et al.
CANCER RESEARCH (2011)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis et al.
NATURE (2010)
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
Zhengying Pan et al.
CHEMMEDCHEM (2007)
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells
VHJ van der Velden et al.
BLOOD (2001)
分享论文
